Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV

A Tale of Two Companies: SG&A Expenses of Viatris Inc. and Galapagos NV

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Galapagos NV from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Galapagos NV in SG&A spending, with expenses peaking at approximately $4.65 billion in 2023, a staggering 400% increase from 2014. In contrast, Galapagos NV's SG&A expenses saw a more modest rise, peaking at around $239 million in 2022, reflecting a 2500% increase from its 2014 figures. This stark contrast highlights Viatris Inc.'s expansive operational scale compared to Galapagos NV's more conservative approach. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.